Enbiocell targets oral semaglutide with ChargeSMEDDS delivery platform

The wire

1. 01Enbiocell, led by CEO Ho-seop Jeong, said it has developed ChargeSMEDDS to convert injectable peptide drugs into oral capsules, with semaglutide as the first target; a domestic patent was filed in April and an overseas filing is being prepared.
2. 02Oral peptide delivery is the main constraint on moving injectable GLP-1s, amylin analogs and insulin to pills, and the company says its capsules can be made by mixing raw materials on existing equipment.
3. 03The platform is still in development; the company says absorption rates and whether it can relax the empty-stomach dosing rules of marketed oral semaglutide must be verified in future research.

From the source

Enbiocell Converts Injectable Obesity Drug into Oral 'Drug'... Begins Oralization of Semaglutide

Peptide drugs used to treat obesity and diabetes are easily broken down by stomach acid and digestive enzymes and have difficulty penetrating the intestinal mucosa, so a significant number are administered as injections. To convert active ingredients into oral medications, technology is required to deliver them to the point where absorption is possible while protecting them from degradation in the